Loading organizations...
§ Private Profile · Berlin, Germany
Develops non-invasive blood glucose monitoring solutions for diabetes patients, utilizing a patented photothermal method.
DiaMonTech AG is a Berlin, Germany-based medical technology company that develops non-invasive blood glucose monitoring solutions utilizing a patented photothermal detection method. The organization's flagship hardware device, the D-Pocket, measures blood sugar levels without finger pricks and has generated letters of intent with global distributors representing approximately $200 million in potential future revenue. The enterprise has secured over $17 million in initial capital and recently completed an €8 million funding round in June 2025 backed by 2,983 individual investors, bringing its total corporate valuation to €80.8 million. DiaMonTech has received strategic financial backing from notable corporate venture arms and healthcare industry leaders, specifically including Samsung Next and Medtronic, while also earning healthcare innovation recognition from Fast Company and MEDICA. The medical device company was established in 2015 by co-founders Werner Mäntele and Thorsten Lubinski.
DiaMonTech AG has raised $23.1M across 3 funding rounds.
DiaMonTech AG has raised $23.1M in total across 3 funding rounds.
DiaMonTech AG has raised $23.1M across 3 funding rounds. Most recently, it raised $9.4M Other Equity in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 16, 2025 | $9.4M Venture Round | Companisto | Samsung Next | Announced |
| Feb 1, 2022 | $6M Series U | — | IBB Ventures | Announced |
| Sep 9, 2019 | $7.7M Series A | Erik Hoppe | IBB Ventures | Announced |
DiaMonTech AG has raised $23.1M in total across 3 funding rounds.
DiaMonTech AG's investors include Companisto, Samsung Next, IBB Ventures, Erik Hoppe.
DiaMonTech AG is a Berlin-based medical technology company developing non-invasive blood glucose monitoring devices using patented mid-infrared laser-based photothermal detection technology, eliminating the need for finger pricks, blood, or test strips.[1][2][4] It targets over 400 million people worldwide with diabetes, primarily Type 2 patients requiring frequent monitoring to prevent complications like cardiovascular disease and kidney failure, while also appealing to non-diabetics for preventive health tracking.[2][4][5] The company offers products like D-BASE (a shoebox-sized desktop device for clinical trials, CE-certified in 2019), D-Pocket (a portable pocket-sized monitor that won the 2023 Healthcare Innovation World Cup), and D-SENSOR (a wearable in development for continuous real-time monitoring).[1][3][5] Growth momentum includes a €12 million funding round from investors like Samsung Next and Companisto to accelerate miniaturization, plus awards such as the 2024 Health-i Award and Deep Tech Berlin Award.[3]
DiaMonTech AG was founded in 2015 in Berlin, Germany, spinning out from over 20 years of research at Goethe University Frankfurt on infrared spectroscopy for glucose detection.[1][2][4] The core innovation emerged from this academic foundation, leading to the patented mid-infrared photothermal deflection spectroscopy (MIR-PTD) technology, validated in a clinical study by the Institute for Diabetes Technology in Ulm comparing it to invasive methods across 100 volunteers.[3][4] Early traction came with CE certification for the D-BASE device in 2019, confirming safety and performance standards, followed by pivotal wins like the 2023 Healthcare Innovation World Cup for D-Pocket and recent €12 million funding to push toward consumer wearables.[3]
DiaMonTech rides the non-invasive diabetes management wave, addressing a €61 million+ European diabetes burden where poor monitoring adherence drives complications and healthcare strain.[4] Timing aligns with medtech miniaturization trends—quantum cascade lasers and photonics enabling smartphone-sized devices—fueled by rising Type 2 diabetes prevalence and demand for wearable health tech like continuous glucose monitors (CGMs).[2][5] Market forces favor it: regulatory nods like CE marking, clinical validation, and funding from deep tech investors position it against incumbents reliant on invasives; it influences Europe's healthtech ecosystem by promoting sustainable, patient-centered innovation and job creation in biotech.[3][4][6]
DiaMonTech is poised to launch consumer wearables like D-SENSOR, leveraging €12 million funding for rapid miniaturization and global scaling, potentially transforming diabetes care for millions.[3][5] Trends like AI-integrated wearables, preventive health for non-diabetics, and photonics advancements will propel it, with partnerships (e.g., Samsung) amplifying reach.[2][3] Its influence may evolve from niche innovator to market leader, easing healthcare burdens if regulatory expansions (e.g., FDA) follow EU success—redefining glucose monitoring as effortless as checking a smartwatch. This builds on its laser-precision origins, delivering the pain-free future promised since 2015.[1][2]